[{"orgOrder":0,"company":"Cessatech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"CT001","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Cessatech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cessatech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Cessatech \/ Inapplicable"},{"orgOrder":0,"company":"Cessatech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"CT001","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Cessatech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cessatech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Cessatech \/ Inapplicable"},{"orgOrder":0,"company":"Cessatech","sponsor":"Proveca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"||Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Cessatech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cessatech \/ Proveca","highestDevelopmentStatusID":"9","companyTruncated":"Cessatech \/ Proveca"},{"orgOrder":0,"company":"Cessatech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"CT001","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cessatech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cessatech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cessatech \/ Inapplicable"},{"orgOrder":0,"company":"Cessatech","sponsor":"Dantrials | Smerud Medical Research International AS","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"CT001","moa":"NMDA receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Cessatech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cessatech \/ Dantrials | Smerud Medical Research International AS","highestDevelopmentStatusID":"6","companyTruncated":"Cessatech \/ Dantrials | Smerud Medical Research International AS"}]